{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:17:16Z","timestamp":1778023036970,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10096-022-04443-2","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T14:03:27Z","timestamp":1650290607000},"page":"827-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incidence and risk factors for mortality in patients treated with combined ceftaroline for Gram-positive infective endocarditis"],"prefix":"10.1007","volume":"41","author":[{"given":"D.","family":"Brandariz-N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Suanzes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Guti\u00e9rrez-Urb\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fern\u00e1ndez-Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Margusino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mart\u00edn-Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"4443_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/archinternmed.2008.603","volume":"169","author":"DR Murdoch","year":"2009","unstructured":"Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS et al (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis prospective cohort study. Arch Intern Med 169:463\u2013473. https:\/\/doi.org\/10.1001\/archinternmed.2008.603","journal-title":"Arch Intern Med"},{"key":"4443_CR2","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMcp1206782","volume":"368","author":"B Hoen","year":"2013","unstructured":"Hoen B, Duval X (2013) Clinical practice. Infective endocarditis. N Engl J Med 368:1425\u20131433. https:\/\/doi.org\/10.1056\/NEJMcp1206782","journal-title":"N Engl J Med"},{"key":"4443_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/heart.83.5.525","volume":"83","author":"JC Castillo","year":"2000","unstructured":"Castillo JC, Anguita MP, Ramirez A, Siles JR, Torres F, Mesa D et al (2000) Long term outcome of infective endocarditis in patients who were not drug addicts: a 10 year study. Heart 83:525\u2013530. https:\/\/doi.org\/10.1136\/heart.83.5.525","journal-title":"Heart"},{"issue":"12","key":"4443_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082665","volume":"8","author":"L Slipczuk","year":"2013","unstructured":"Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS, Figueredo VM (2013) Infective endocarditis epidemiology over five decades: a systematic review. PLoS ONE 8(12):e82665. https:\/\/doi.org\/10.1371\/journal.pone.0082665","journal-title":"PLoS ONE"},{"key":"4443_CR5","unstructured":"Zinforo\u00ae (ceftaroline fosamil). Full prescribing information. EMEA. Accessed October 25, 2021.Available at: https:\/\/ec.europa.eu\/health\/documents\/communityregister\/2014\/20141030130093\/anx_130093_es.pdf"},{"key":"4443_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/jac\/dks006","volume":"67","author":"TT Ho","year":"2012","unstructured":"Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd (2012) Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 67:1267\u20131270. https:\/\/doi.org\/10.1093\/jac\/dks006","journal-title":"J Antimicrob Chemother"},{"key":"4443_CR7","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1128\/AAC.02371-13","volume":"58","author":"AM Casapao","year":"2014","unstructured":"Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE et al (2014) Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 58:2541\u20132546. https:\/\/doi.org\/10.1128\/AAC.02371-13","journal-title":"Antimicrob Agents Chemother"},{"key":"4443_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40121-019-00277-2","volume":"9","author":"O Ahmad","year":"2020","unstructured":"Ahmad O, Crawford TN, Myint T (2020) Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus monotherapy in adults with complicated and prolonged methicillin-resistant Staphylococcus aureus bacteremia initially treated with supplemental ceftaroline. Infect Dis Ther 9:77\u201387. https:\/\/doi.org\/10.1007\/s40121-019-00277-2","journal-title":"Infect Dis Ther"},{"key":"4443_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","volume":"53","author":"CJ Destache","year":"2019","unstructured":"Destache CJ, Guervil DJ, Kaye KS (2019) Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents 53:644\u2013649. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.01.014","journal-title":"Int J Antimicrob Agents"},{"key":"4443_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1086\/313753","volume":"30","author":"JS Li","year":"2000","unstructured":"Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30:633\u2013638. https:\/\/doi.org\/10.1086\/313753","journal-title":"Clin Infect Dis"},{"key":"4443_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, Mackenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chron Dis"},{"key":"4443_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287","journal-title":"JAMA"},{"issue":"14","key":"4443_CR13","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1161\/01.CIR.0000124719.61827.7F","volume":"109","author":"VH Chu","year":"2004","unstructured":"Chu VH, Cabell CH, Benjamin DK Jr, Kuniholm EF, Fowler VG Jr, Engemann J, Sexton DJ, Corey GR et al (2004) Early predictors of in-hospital death in infective endocarditis. Circulation 109(14):1745\u20131749. https:\/\/doi.org\/10.1161\/01.CIR.0000124719.61827.7F","journal-title":"Circulation"},{"issue":"2","key":"4443_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/eurheartj\/ehl427","volume":"28","author":"EE Hill","year":"2007","unstructured":"Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods MC, Peetermans WE (2007) Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J 28(2):196\u2013203. https:\/\/doi.org\/10.1093\/eurheartj\/ehl427","journal-title":"Eur Heart J"},{"key":"4443_CR15","doi-asserted-by":"publisher","unstructured":"Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, Popescu BA, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study.\u00a0Eur Heart J 2019;40:3222\u20133232. https:\/\/doi.org\/10.1093\/eurheartj\/ehz620","DOI":"10.1093\/eurheartj\/ehz620"},{"issue":"4","key":"4443_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.003016","volume":"5","author":"LP Park","year":"2016","unstructured":"Park LP, Chu VH, Peterson G, Skoutelis A, Lejko-Zupa T, Bouza E et al (2016) Validated risk score for predicting 6-month mortality in infective endocarditis. J Am Heart Assoc 5(4):e003016. https:\/\/doi.org\/10.1161\/JAHA.115.003016","journal-title":"J Am Heart Assoc"},{"key":"4443_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2019.03.006","volume":"64","author":"C Armi\u00f1anzas","year":"2019","unstructured":"Armi\u00f1anzas C, Fari\u00f1as-Alvarez C, Zarauza J, Mu\u00f1oz P, Gonz\u00e1lez Ramallo V, Mart\u00ednez Sell\u00e9s M et al (2019) Role of age and comorbidities in mortality of patients with infective endocarditis. Eur J Intern Med 64:63\u201371. https:\/\/doi.org\/10.1016\/j.ejim.2019.03.006","journal-title":"Eur J Intern Med"},{"key":"4443_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/cdt.2016.08.09","volume":"7","author":"A Cresti","year":"2017","unstructured":"Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, D\u2019Aiello I, Picchi A et al (2017) Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. Cardiovasc Diagn Ther 7:27\u201335. https:\/\/doi.org\/10.21037\/cdt.2016.08.09","journal-title":"Cardiovasc Diagn Ther"},{"issue":"1","key":"4443_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/jama.2018.7596","volume":"320","author":"A Wang","year":"2018","unstructured":"Wang A, Gaca JG, Chu VH (2018) Management considerations in infective endocarditis: a review. JAMA 320(1):72\u201383. https:\/\/doi.org\/10.1001\/jama.2018.7596","journal-title":"JAMA"},{"issue":"6","key":"4443_CR20","doi-asserted-by":"publisher","first-page":"ofab119","DOI":"10.1093\/ofid\/ofab119","volume":"8","author":"JM Peric\u00e0s","year":"2021","unstructured":"Peric\u00e0s JM, Hern\u00e1ndez-Meneses M, Mu\u00f1oz P, \u00c1lvarez-Ur\u00eda A, Pinilla-Llorente B, de Alarc\u00f3n A et al (2021) Outcomes and risk factors of septic shock in patients with infective endocarditis: a prospective cohort study. Open Forum Infect Dis 8(6):ofab119. https:\/\/doi.org\/10.1093\/ofid\/ofab119","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"4443_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/SHK.0000000000001013","volume":"49","author":"V Krajinovic","year":"2018","unstructured":"Krajinovic V, Ivancic S, Gezman P, Barsic B (2018) Association between cardiac surgery and mortality among patients with infective endocarditis complicated by sepsis and septic shock. Shock 49(5):536\u2013542. https:\/\/doi.org\/10.1097\/SHK.0000000000001013","journal-title":"Shock"},{"key":"4443_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jacc.2016.10.066","volume":"69","author":"TJ Cahill","year":"2017","unstructured":"Cahill TJ, Baddour LM, Habib G, Hoen B, Salaun E, Pettersson GB, Sch\u00e4fers HJ, Prendergast BD (2017) Challenges in Infective Endocarditis. J Am Coll Cardiol 69:325\u2013344. https:\/\/doi.org\/10.1016\/j.jacc.2016.10.066","journal-title":"J Am Coll Cardiol"},{"key":"4443_CR23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1136\/hrt.2008.152975","volume":"95","author":"VH Chu","year":"2009","unstructured":"Chu VH, Miro JM, Hoen B, Cabell CH, Pappas PA, Jones P, Stryjewski ME, Anguera I, Braun S, Mu\u00f1oz P, Commerford P et al (2009) Coagulase-negative Staphylococcal prosthetic valve endocarditis\u2014a contemporary update based on the international collaboration on endocarditis. Heart 95:570\u2013576. https:\/\/doi.org\/10.1136\/hrt.2008.152975","journal-title":"Heart"},{"key":"4443_CR24","doi-asserted-by":"publisher","unstructured":"Carugati M, Petti CA, Arnold C, Miro JM, Peric\u00e0s JM, Garcia de la Maria C, Kanafani Z, et al. Antistaphylococcal \u03b2-Lactams versus vancomycin for treatment of infective endocarditis due to methicillin-susceptible coagulase-negative Staphylococci: a prospective cohort study from the international collaboration on endocarditis.\u00a0Antimicrob Agents Chemother 2016;60:6341\u20136349. https:\/\/doi.org\/10.1128\/AAC.01531-16","DOI":"10.1128\/AAC.01531-16"},{"key":"4443_CR25","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3904\/kjim.2017.098","volume":"34","author":"EJ Joo","year":"2019","unstructured":"Joo EJ, Park DA, Kang CI, Chung DR, Song JH, Lee SM et al (2019) Reevaluation of the impact of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and endocarditis. Korean J Intern Med 34:1347\u20131362. https:\/\/doi.org\/10.3904\/kjim.2017.098","journal-title":"Korean J Intern Med"},{"key":"4443_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115153","volume":"98","author":"R Rodr\u00edguez-Garc\u00eda","year":"2020","unstructured":"Rodr\u00edguez-Garc\u00eda R, Rodr\u00edguez-Esteban M\u00c1, Garc\u00eda-Car\u00fas E, Telenti M, Fern\u00e1ndez J (2020) In vitro activity of ceftaroline and ceftobiprole against clinical isolates of Gram-positive bacteria from infective endocarditis: are these drugs potential options for the initial management of this disease? Diagn Microbiol Infect Dis 98:115153. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115153","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4443_CR27","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1128\/AAC.04614-14","volume":"59","author":"HS Sader","year":"2015","unstructured":"Sader HS, Flamm RK, Streit JM, Farrell DJ, Jones RN (2015) Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. Antimicrob Agents Chemother 59:2458\u201361. https:\/\/doi.org\/10.1128\/AAC.04614-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"19\u201332","key":"4443_CR28","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.1093\/jac\/dkr096","volume":"66","author":"TM File Jr","year":"2011","unstructured":"File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J et al (2011) FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(19\u201332):iii. https:\/\/doi.org\/10.1093\/jac\/dkr096","journal-title":"J Antimicrob Chemother"},{"issue":"33\u201344","key":"4443_CR29","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.1093\/jac\/dkr097","volume":"66","author":"DE Low","year":"2011","unstructured":"Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J et al (2011) FO- CUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(33\u201344):iii. https:\/\/doi.org\/10.1093\/jac\/dkr097","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04443-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-022-04443-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04443-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:08:48Z","timestamp":1650625728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-022-04443-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4443"],"URL":"https:\/\/doi.org\/10.1007\/s10096-022-04443-2","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was evaluated and approved by the Ethics Committee for Medicines of Galicia (CEIm-G) with registration code 2021\/268.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}